|
Volumn 143, Issue 3, 2007, Pages 413-415
|
Topical hydrocortisone from prescription to over-the-counter sale: A past controversy: A cautionary tale
|
Author keywords
[No Author keywords available]
|
Indexed keywords
BENZOCAINE;
HYDROCORTISONE;
NON PRESCRIPTION DRUG;
ROFECOXIB;
SALICYLIC ACID;
TAR;
CREAM;
CUSHING SYNDROME;
DELAYED DIAGNOSIS;
DRUG APPROVAL;
DRUG FORMULATION;
DRUG MARKETING;
DRUG SAFETY;
FOOD AND DRUG ADMINISTRATION;
GENETIC PREDISPOSITION;
HUMAN;
IMMUNE DEFICIENCY;
MEDICAL SOCIETY;
NONHUMAN;
NOTE;
PERIORAL DERMATITIS;
POSTMARKETING SURVEILLANCE;
PRESCRIPTION;
PRIORITY JOURNAL;
PRURITUS;
RASH;
RISK ASSESSMENT;
RISK BENEFIT ANALYSIS;
ROSACEA;
SELF EVALUATION;
SELF MEDICATION;
SKIN ATROPHY;
SKIN CANCER;
SKIN CARE;
SKIN DISEASE;
SKIN INFLAMMATION;
STRIA;
TELANGIECTASIA;
UNITED STATES;
ADMINISTRATION, TOPICAL;
ANTI-INFLAMMATORY AGENTS;
DRUGS, NON-PRESCRIPTION;
HUMANS;
HYDROCORTISONE;
|
EID: 33947521887
PISSN: 0003987X
EISSN: 0003987X
Source Type: Journal
DOI: 10.1001/archderm.143.3.413 Document Type: Note |
Times cited : (10)
|
References (14)
|